Nearly a third of patients with advanced liver cancer who received a personalized vaccine developed by Geneos Therapeutics along with an immunotherapy drug in a small, early trial saw their tumors shrink, U.S. researchers reported on Sunday. The result was roughly twice the response typically seen with the immunotherapy alone, Read this story
